HC Wainwright Forecasts Ocugen’s Q1 Earnings (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN) – Analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of Ocugen in a note issued to investors on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.05) per share for the quarter, down from their previous estimate of ($0.04). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen’s Q2 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, FY2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.11) EPS and FY2028 earnings at $0.21 EPS.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Ocugen had a negative return on equity of 154.75% and a negative net margin of 532.51%. During the same period in the previous year, the firm posted ($0.03) EPS.

Separately, Chardan Capital increased their target price on Ocugen from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th.

Ocugen Trading Down 1.8 %

Shares of OCGN opened at $0.55 on Monday. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $159.61 million, a P/E ratio of -3.04 and a beta of 3.88. The stock’s fifty day simple moving average is $0.72 and its 200 day simple moving average is $0.89. Ocugen has a twelve month low of $0.52 and a twelve month high of $2.11.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC raised its position in Ocugen by 104.3% in the third quarter. Barclays PLC now owns 581,087 shares of the company’s stock valued at $577,000 after purchasing an additional 296,654 shares during the period. Rhumbline Advisers raised its position in Ocugen by 12.9% in the fourth quarter. Rhumbline Advisers now owns 324,475 shares of the company’s stock valued at $261,000 after purchasing an additional 37,034 shares during the period. State Street Corp raised its position in Ocugen by 7.1% in the third quarter. State Street Corp now owns 15,824,517 shares of the company’s stock valued at $15,701,000 after purchasing an additional 1,047,896 shares during the period. SG Americas Securities LLC raised its position in Ocugen by 72.7% in the fourth quarter. SG Americas Securities LLC now owns 152,176 shares of the company’s stock valued at $123,000 after purchasing an additional 64,080 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Ocugen by 6.3% during the third quarter. Geode Capital Management LLC now owns 6,278,554 shares of the company’s stock valued at $6,231,000 after acquiring an additional 373,555 shares in the last quarter. 10.27% of the stock is owned by hedge funds and other institutional investors.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.